Development of cardiovascular implant using nanocomposite polymer and stem cell technology: from lab to commercialisation

Cardiovascular implants including bypass grafts, heart valves and stents are prone to calcification, thrombogenicity and structural failure. To overcome these problems we have developed and patented a family of nanocomposite polymers based on polyhedral oligomeric silsesquioxane (POSS) nanoparticles and poly(carbonate urea)urethane (PCU). In addition, we have been working on bonding bioactive molecules and peptides to attract progenitor stem cells from peripheral circulating blood onto the implants with the aim of differentiating them into endothelial cells; these are the cell types which cover the cardiovascular system. At this meeting I will be presenting out data on biocompatibility, biostability, calcification resistance and anti-thrombogenicity of this polymer tested in vitro and in vivo. Currently this polymer has been used for manufacturing small diameter conduits for coronary artery bypass grafts, heart valves as well as coating stents. Data on manufacturing and evaluation as well as in vitro and preclinical in vivo testing will be presented. In conclusion these results, together with its ease of manufacture and low cost, suggest that POSS-PCU nanocomposite could be an attractive material of choice for the development of cardiovascular implants.